Clinical stage pharmaceutical development Company
Algernon Pharmaceuticals Inc. (
CSE: AGN, OTCQB: BTHCF, Forum) reported Wednesday that its drugs for treating non-alcoholic steatohepatitis and chronic kidney disease,
Bemethyl (NP-135) and
Bromantane (NP-160), outperformed known anti-fibrotic agents. Both drugs are types of “actoprotectors”, developed as athletic performance enhancing drugs by the Soviet Union.
For more on this news,
click here.
Earlier this Monday,
AGN stated that its lead compound to treat a type of chronic lung disease, NP-120, contains a key ingredient for its research program - a drug called
Ifenprodil. In two studies conducted by the Company, NP-120 outperformed the world’s leading two treatments for idiopathic pulmonary fibrosis (IPF).
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.